|
Research and Development:
| Project Name |
Pathogen/Indication |
Current Status |
| VG-WNV |
West Nile Virus |
Supporting results in animal models (5 repetitions, 3 virus strains) |
| VG-LC |
Lung Cancer |
Successfully repeated animal experiments with two antigen sources |
|
|
|
Business Development:
VacciGuard has signed an agreement with a large US vaccine company to support the proof-of-concept of one of the projects.
Fund raising:
VacciGuard has successfully raised some funds from a private investor. VacciGuard is seeking an additional $2M to support the phase I/II clinical development of one of the projects.
|